Phasei Trial Support Best In Class Potential News Today : Breaking News, Live Updates & Top Stories | Vimarsana

InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update -November 01, 2023 at 09:13 am EDT

Jena, Germany, November 1, 2023 - InflaRx N.V. , a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results.

United statesThomas taapkenGerman ministry of educationDevelopment expensesDevelopment of vilobelimabDrug administrationEuropean medicines agencyInflarx stops development of vilobelimabEuropean unionGerman ministry of healthRecent highlightsBusiness updateTopline resultsSingle ascending dosePhasei trial support best in class potentialPyoderma gangrenosum

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNielsc riedemannLaurie doyleRegina lutzThomas taapkenKatja arnoldDrug administrationInflarx pharmaceuticals incDevelopment of vilobelimabGerman ministry of educationMc servicesExchange commissionGerman ministry of healthDevelopment expensesEuropean medicines agencyEuropean union

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) .

United statesThomas taapkenNielsc riedemannRegina lutzLaurie doyleKatja arnoldInflarx stops development of vilobelimabInflarx pharmaceuticals incDevelopment expensesEuropean unionGerman ministry of educationMc servicesEuropean medicines agencyDevelopment of vilobelimabExchange commissionDrug administration